This case was initially received via regulatory authority ansm (reference number: (b)(4)) on 29-sep-2017.This spontaneous case was reported by a consumer and describes the occurrence of pelvic pain ("pelvic pains") in a female patient who had essure (batch no.C26933) inserted.The occurrence of additional non-serious events is detailed below.On (b)(6) 2014, the patient had essure inserted.On an unknown date, the patient experienced pelvic pain (seriousness criteria medically significant and intervention required), tinnitus ("tinnitus"), fatigue ("fatigue"), dyspnoea ("out of breath"), dyspepsia ("digestive disorders"), allergy to metals ("titanium and nickel allergy"), eczema ("eczema"), burning sensation ("burning"), cystitis ("cystitis"), fungal infection ("mycosis"), headache ("headaches") and asthma ("asthma").The patient was treated with surgery (removal of essure was planned).Essure treatment was not changed.At the time of the report, the pelvic pain, tinnitus, fatigue, dyspnoea, dyspepsia, allergy to metals, eczema, burning sensation, cystitis, fungal infection, headache and asthma outcome was unknown.The reporter provided no causality assessment for allergy to metals, asthma, burning sensation, cystitis, dyspepsia, dyspnoea, eczema, fatigue, fungal infection, headache, pelvic pain and tinnitus with essure.The reporter commented: the event happened at the home of the patient.Quality-safety evaluation of ptc: unable to confirm complaint.Most recent follow-up information incorporated above includes: on (b)(6) 2017: quality safety evaluation of ptc.The list of device similar incidents contains essure reports received by bayer and older cases received by conceptus coded with the same medra preferred term.In this particular case a search in the database was performed on (b)(6) 2017 for the following meddra preferred term: pelvic pain.The analysis in the global safety database revealed (b)(4) cases.Bayer is closely monitoring the benefit-risk profile of essure.A recent cumulative review of all available data on essure has not yielded any new safety signal with regard to this meddra pt.Further company follow-up with the regulatory authority is not possible.Incident: at the time of reporting, there is no evidence that a device-related defect or malfunction caused a death or serious injury.If additional information becomes available it will be provided on a supplemental report.
|